Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Pyrotinib + AI in Elderly Advanced Triple-Positive Breast Cancer
NCT06235931Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib and pyrotinib in triple-positive breast cancer (TPBC), sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoint: Progression Free Survival at 29 months. Started Feb 2024; status: recruiting.
02
Drugs
dalpiciclibpyrotinib
03
Conditions
triple-positive breast cancer (TPBC)
Beyond the preview
Go deeper on NCT06235931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235931.